Okcu Oğuzhan, Öztürk Çiğdem, Yalçın Anıl Can, Şen Bayram, Yalçın Nazlıcan, Hacıhasanoğlu Ezgi, Aydın Esra
Recep Tayyip Erdoğan University, Faculty of Medicine, Department of Pathology - Rize, Türkiye.
Recep Tayyip Erdoğan University Training and Research Hospital, Department of Pathology - Rize, Türkiye.
Rev Assoc Med Bras (1992). 2025 Mar 31;71(2):e20241225. doi: 10.1590/1806-9282.20241225. eCollection 2025.
Breast cancer is the most common cancer type among women. One of the most important parameters in the prognosis of patients is the response to neoadjuvant chemotherapy. The most important parameter for neoadjuvant chemotherapy success is appropriate patient selection. We investigated the effect of tumor-stroma type and tumor-stroma ratio on neoadjuvant chemotherapy response, using the Residual Cancer Burden scoring systems.
Patients diagnosed with breast carcinoma in core needle biopsy materials between 2010 and 2023 and whose neoadjuvant treatments and surgeries were performed in our institution were scanned from the database. A total of 158 patients who met the study criteria were included in the study.
Tumor-stroma ratio and collagen-dominant tumor-stroma type were associated with neoadjuvant chemotherapy resistance, and tumor-stroma ratio was found to be an independent risk factor in treatment response. The probability of response to neoadjuvant chemotherapy treatment was higher in luminal molecular subtype breast cancer patients with low tumor stroma.
An effective risk analysis for neoadjuvant chemotherapy treatment is not always possible with current clinicopathological parameters. Tumor-stroma ratio and tumor-stroma type seem useful in predicting neoadjuvant chemotherapy response as a reproducible practical marker and do not require additional cost and time.
乳腺癌是女性中最常见的癌症类型。患者预后的最重要参数之一是对新辅助化疗的反应。新辅助化疗成功的最重要参数是合适的患者选择。我们使用残余癌负担评分系统研究了肿瘤-基质类型和肿瘤-基质比率对新辅助化疗反应的影响。
从数据库中扫描2010年至2023年期间在粗针活检材料中被诊断为乳腺癌且在我们机构接受新辅助治疗和手术的患者。共有158名符合研究标准的患者纳入研究。
肿瘤-基质比率和以胶原为主的肿瘤-基质类型与新辅助化疗耐药相关，且肿瘤-基质比率被发现是治疗反应的独立危险因素。肿瘤基质低的管腔分子亚型乳腺癌患者对新辅助化疗治疗有反应的概率更高。
使用当前的临床病理参数并不总是能够对新辅助化疗治疗进行有效的风险分析。肿瘤-基质比率和肿瘤-基质类型作为一种可重复的实用标志物，在预测新辅助化疗反应方面似乎很有用，且不需要额外的成本和时间。
